Funder
Japan Agency for Medical Research and Development
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference15 articles.
1. Minami H, Kiyota N, Kimbara S, et al. Guidelines for clinical evaluation of anti-cancer drugs. Cancer Sci. 2021;112:2563–77.
2. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
3. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer. 2006;42:1031–9.
4. Watanabe S, Nonaka T, Maeda M, et al. Fact-finding research on efficacy endpoints in recent Phase II clinical trials targeting glioblastoma. Pharm Med Dev Regul Sci. 2021;52:358–67.
5. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231–51.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献